Sanofi (SNY) Net Cash Flow (2009 - 2026)
Sanofi (SNY) posted Net Cash Flow of $918.3 million for Q2 2026, up 136.96% sequentially from -$2.5 billion in Q1 2026, and down 88.52% YoY from $8.0 billion in Q2 2025.
Sanofi (SNY) Net Cash Flow (2009 - 2026) Analysis & Trends
Sanofi has reported Net Cash Flow for 9 years, with the latest figure at $918.3 million in Q2 2026.
- Quarterly Net Cash Flow fell 88.52% year-over-year to $918.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$1.1 billion (down 106.97% YoY) and the FY2025 annual result came in at $111.7 million, up 109.6% from the prior year.
- Net Cash Flow advanced to $918.3 million in Q2 2026 per SNY's latest filing, from -$2.5 billion in the prior quarter.
- Over five years, Net Cash Flow peaked at $12.0 billion in Q4 2023 and troughed at -$2.6 billion in Q2 2024.
- A 5-year average of $2.9 billion and a median of $1.1 billion in 2022 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2025 and 2026: Net Cash Flow soared 412.42% in 2025, then slumped 425.76% in 2026.
- Over 5 years, Net Cash Flow stood at $11.2 billion in 2022, then increased by 6.9% to $12.0 billion in 2023, then plunged by 103.03% to -$362.3 million in 2024, then sank by 221.33% to -$1.2 billion in 2025, then jumped by 178.89% to $918.3 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered $918.3 million, -$2.5 billion, and -$1.2 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | -1.27 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -2.82 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 1.53 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 757.00 Mn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -6.80 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 1.95 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -4.43 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -722.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 2.68 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 27.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 918.27 Mn |
| Jun 30, 2026 | 918.27 Mn |
| Mar 31, 2026 | -2.48 Bn |
| Mar 31, 2026 | -2.48 Bn |
| Dec 31, 2025 | -1.16 Bn |
| Dec 31, 2025 | -1.16 Bn |
| Sep 30, 2025 | 1.58 Bn |
| Sep 30, 2025 | 1.58 Bn |
| Jun 30, 2025 | 8.00 Bn |
| Jun 30, 2025 | 8.00 Bn |
| Mar 31, 2025 | 762.62 Mn |
| Mar 31, 2025 | 762.62 Mn |
| Dec 31, 2024 | -362.25 Mn |
| Dec 31, 2024 | -362.25 Mn |
| Sep 30, 2024 | 8.09 Bn |
| Sep 30, 2024 | 8.09 Bn |
| Jun 30, 2024 | -2.56 Bn |
| Jun 30, 2024 | -2.56 Bn |
| Mar 31, 2024 | 517.11 Mn |
| Mar 31, 2024 | 517.11 Mn |